36894-69-6

• 常用中文名：拉贝洛尔
• 常用英文名：Labetalol
• CAS号：36894-69-6
• 分子式：C₁₉H₂₄N₂O₃
• 分子量：328.405
• 相关类别： 原料药 循环系统用药 抗高血压病药
• 发布时间：2018-02-07 08:00:00
• 更新时间：2024-01-05 17:30:37
• 拉贝洛尔(AH5158)是一种口服活性选择性α1-和非选择性β-肾上腺素能受体竞争性拮抗剂。拉贝洛尔是一种抗高血压药物,可用于心血管疾病的研究,如妊娠高血压[1][2][3]。

名称

• 中文名: 拉贝洛尔
• 英文名: labetalol
• 中文别名: 2-羟基-5-{1-羟基-2-[(1-甲基-3-苯基丙基)氨基]乙基}苯甲酰胺; 拉本他乐
• 英文别名: 2-Hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide; 2-Hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide hydrochloride (1:1); Amipress; MFCD00242941; Labetalol hydrochloride; benzamide, 2-hydroxy-5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl]-, monohydrochloride; Labetalol; Benzamide, 2-hydroxy-5-(1-hydroxy-2-((1-methyl-3-phenylpropyl)amino)ethyl)-; Pressalolo; Trandate; 2-Hydroxy-5-{1-hydroxy-2-[(4-phenyl-2-butanyl)amino]ethyl}benzamide; Salicylamide, 5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl]-, hydrochloride; Benzamide, 2-hydroxy-5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl]-, hydrochloride (1:1); Benzamide, 2-hydroxy-5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl]-; Labrocol; 2-hydroxy-5-{1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl}benzamide hydrochloride; 2-Hydroxy-5-{1-hydroxy-2-[(4-phenyl-2-butanyl)amino]ethyl}benzamide hydrochloride (1:1); 2-Hydroxy-5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl]benzamide hydrochloride; 2-Hydroxy-5-(1-hydroxy-2-((4-phenylbutan-2-yl)amino)ethyl)benzamide hydrochloride; 2-hydroxy-5-[1-hydroxy-2-(4-phenylbutan-2-ylamino)ethyl]benzamide,hydrochloride; 5-[1-Hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl]salicylamide hydrochloride; 2-hydroxy-5-{1-hydroxy-2-[(1-méthyl-3-phénylpropyl)amino]éthyl}benzamide chlorhydrate; rac Labetalol; labetolol; Ipolab; UNII:R5H8897N95; 2-Hydroxy-5-{1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl}benzolcarboxamidhydrochlorid; LABETALOL HCL; EINECS 253-258-3

物化性质

• 密度: 1.2±0.1 g/cm3
• 沸点: 552.7±50.0 °C at 760 mmHg
• 分子式: C₁₉H₂₄N₂O₃
• 分子量: 328.405
• 闪点: 288.1±30.1 °C
• 精确质量: 328.178680
• PSA: 95.58000
• LogP: 2.31
• 蒸汽压: 0.0±1.6 mmHg at 25°C
• 折射率: 1.609
• 储存条件: 2-8°C

生物活性

• 描述: 拉贝洛尔(AH5158)是一种口服活性选择性α1-和非选择性β-肾上腺素能受体竞争性拮抗剂。拉贝洛尔是一种抗高血压药物,可用于心血管疾病的研究,如妊娠高血压[1][2][3]。
• 相关类别:
  研究领域 >> 心血管疾病
  信号通路 >> G 蛋白偶联受体/G 蛋白 >> 肾上腺素能受体
  研究领域 >> 炎症/免疫
• 靶点:

  α1-adrenergic receptor

  β-adrenoceptor

• 体外研究: 拉贝洛尔对豚鼠心脏和肺膜上的β-肾上腺素能位点表现出更大的亲和力(IC50分别为0.8和4.0μM)[2]。拉贝洛尔对兔子宫膜上的α-肾上腺素能结合位点(IC50=15μm)有亲和力。Labctalol对心脏膜β结合位点的结合亲和力是子宫膜α结合位点的19倍[2]。
• 体内研究: 拉贝洛尔(10 mg/kg；i.h.)通过血脑屏障,在注射后90分钟,在10天大鼠幼鼠大脑中达到2.1 ug/g组织水平[4]。拉贝洛尔(5.0 mg/kg；i.p.)可减弱尾波休克应激大鼠的循环IL-1β和IL-6[5]。
• 参考文献:

  [1]. Brogden RN, et al. Labetalol: a review of its pharmacology and therapeutic use in hypertension. Drugs. 1978;15(4):251-270.

  [2]. Greenslade FC, et al. Labetalol binding to specific alpha- and beta-adrenergic sites in vitro and its antagonism of adrenergic responses in vivo. J Mol Cell Cardiol. 1979 Aug;11(8):803-11.

  [3]. Easterling T, et al. Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial. Lancet. 2019 Sep 21;394(10203):1011-1021.

  [4]. Erdtsieck-Ernste EB, et al. Changes in adrenoceptors and monoamine metabolism in neonatal and adult rat brain after postnatal exposure to the antihypertensive labetalol. Br J Pharmacol. 1992 Jan;105(1):37-44.

  [5]. Johnson JD, et al. Catecholamines mediate stress-induced increases in peripheral and central inflammatory cytokines. Neuroscience. 2005;135(4):1295-307.

毒性和生态

CHEMICAL IDENTIFICATION RTECS NUMBER : CV5375500 CHEMICAL NAME : Benzamide, 2-hydroxy-5-(1-hydroxy-2-((1-methyl-3-phenylpropyl)am ino)ethyl)- CAS REGISTRY NUMBER : 36894-69-6 LAST UPDATED : 199612 DATA ITEMS CITED : 7 MOLECULAR FORMULA : C19-H24-N2-O3 MOLECULAR WEIGHT : 328.45 WISWESSER LINE NOTATION : ZVR BQ EYQ1MY1&2R HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - man DOSE/DURATION : 8571 mg/kg/D TOXIC EFFECTS : Behavioral - changes in psychophysiological tests REFERENCE : BMJOAE British Medical Journal. (British Medical Assoc., BMA House, Tavistock Sq., London WC1H 9JR, UK) V.1- 1857- Volume(issue)/page/year: 282,1824,1981 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human DOSE/DURATION : 240 mg/kg/14D TOXIC EFFECTS : Peripheral Nerve and Sensation - paresthesis REFERENCE : BMJOAE British Medical Journal. (British Medical Assoc., BMA House, Tavistock Sq., London WC1H 9JR, UK) V.1- 1857- Volume(issue)/page/year: 1,580,1978 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - woman DOSE/DURATION : 2 mg/kg TOXIC EFFECTS : Skin and Appendages - dermatitis, allergic (after systemic exposure) REFERENCE : AIMEAS Annals of Internal Medicine. (American College of Physicians, 4200 Pine St., Philadelphia, PA 19104) V.1- 1927- Volume(issue)/page/year: 104,729,1986 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >2 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : PBPSDY Pharmacological and Biochemical Properties of Drug Substances. (American Pharmaceutical Assoc., 2215 Constitution Ave., NW, Washington, DC 20037) V.1- 1977- Volume(issue)/page/year: 2,229,1979 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >50 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : PBPSDY Pharmacological and Biochemical Properties of Drug Substances. (American Pharmaceutical Assoc., 2215 Constitution Ave., NW, Washington, DC 20037) V.1- 1977- Volume(issue)/page/year: 2,229,1979 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 660 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : USXXAM United States Patent Document. (U.S. Patent Office, Box 9, Washington, DC 20231) Volume(issue)/page/year: #5326774 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 97500 ug/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : USXXAM United States Patent Document. (U.S. Patent Office, Box 9, Washington, DC 20231) Volume(issue)/page/year: #5326774

安全

• 危害码 (欧洲): Xi
• 海关编码: 2924299090

上下游产品

上游产品  0
下游产品  2
22374-89-6 76143-20-9

海关

海关编码	2924299090
中文概述	2924299090. 其他环酰胺（包括环氨基甲酸酯）（包括其衍生物以及他们的盐）. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:30.0%
申报要素	品名, 成分含量, 用途, 包装
Summary	2924299090. other cyclic amides (including cyclic carbamates) and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0%